ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: Results of a Phase I trial

M Ronson; Lisette Hammond; David Ferry; M Kris; A Tullo; Philip Murray; V Miller; S Averbuch; J Ochs; C Morris; A Feyereislova; H Swaisland; EK Rowinsky

doi:10.1200/JCO.2002.10.112

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: Results of a Phase I trial

M Ronson, Lisette Hammond, David Ferry, M Kris, A Tullo, Philip Murray, V Miller, S Averbuch, J Ochs, C Morris, A Feyereislova, H Swaisland, EK Rowinsky

Immunology and Immunotherapy

Research output: Contribution to journal › Article

729 Citations (Scopus)

Original language	English
Pages (from-to)	2240-2250
Number of pages	11
Journal	Journal of Clinical Oncology
Volume	20
Issue number	9
DOIs	https://doi.org/10.1200/JCO.2002.10.112
Publication status	Published - 1 May 2002

Access to Document

10.1200/JCO.2002.10.112

Cite this

Ronson, M., Hammond, L., Ferry, D., Kris, M., Tullo, A., Murray, P., Miller, V., Averbuch, S., Ochs, J., Morris, C., Feyereislova, A., Swaisland, H., & Rowinsky, EK. (2002). ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: Results of a Phase I trial. Journal of Clinical Oncology, 20(9), 2240-2250. https://doi.org/10.1200/JCO.2002.10.112

@article{b5faaf9db2ea40b9bfa971c3f1dc1233,

title = "ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: Results of a Phase I trial",

author = "M Ronson and Lisette Hammond and David Ferry and M Kris and A Tullo and Philip Murray and V Miller and S Averbuch and J Ochs and C Morris and A Feyereislova and H Swaisland and EK Rowinsky",

year = "2002",

month = may,

day = "1",

doi = "10.1200/JCO.2002.10.112",

language = "English",

volume = "20",

pages = "2240--2250",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "9",

}

Ronson, M, Hammond, L, Ferry, D, Kris, M, Tullo, A, Murray, P, Miller, V, Averbuch, S, Ochs, J, Morris, C, Feyereislova, A, Swaisland, H & Rowinsky, EK 2002, 'ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: Results of a Phase I trial', Journal of Clinical Oncology, vol. 20, no. 9, pp. 2240-2250. https://doi.org/10.1200/JCO.2002.10.112

TY - JOUR

T1 - ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: Results of a Phase I trial

AU - Ronson, M

AU - Hammond, Lisette

AU - Ferry, David

AU - Kris, M

AU - Tullo, A

AU - Murray, Philip

AU - Miller, V

AU - Averbuch, S

AU - Ochs, J

AU - Morris, C

AU - Feyereislova, A

AU - Swaisland, H

AU - Rowinsky, EK

PY - 2002/5/1

Y1 - 2002/5/1

UR - http://www.scopus.com/inward/record.url?scp=0036569870&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.10.112

DO - 10.1200/JCO.2002.10.112

M3 - Article

SN - 1527-7755

VL - 20

SP - 2240

EP - 2250

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 9

ER -